Can Fite (Israel) Valuation Overview

CANF -- Israel Stock  

ILS 237.90  1.40  0.58%

Can Fite BioPharma shows prevailing Real Value of S235.52 per share. The current price of the firm is S237.9. At this time the firm appears to be fairly valued. Macroaxis approximates value of Can Fite BioPharma from analyzing the firm fundamentals such as Shares Outstanding of 40.36M, Return On Equity of (111.36)% and Operating Margin of (454.47)% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.
Horizon     30 Days    Login   to change
Can Fite BioPharma Ltd is rated fifth in price to sales category among related companies. It is rated below average in beta category among related companies totaling about  0.01  of Beta per Price to Sales. The ratio of Price to Sales to Beta for Can Fite BioPharma Ltd is roughly  88.26 

Current Market Valuation

Can Fite BioPharma Valuation Boundaries

Fairly Valued
December 13, 2018
Market Value
Real Value
Target Odds
Can Fite is not too risky asset. Calculation of real value of Can Fite BioPharma is based on 2 months time horizon. Increasing Can Fite BioPharma time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Check also Trending Equities. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.